TrialThe Lancet. Respiratory medicine2018
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.
Margaret Rosenfeld et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
112 papers cite itlatest 60 shown
this paperpooled ittrialcites it